Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3195 and Pembrolizumab in Advanced Solid Tumors
NCT07469774Phase 2Recruiting
- Sponsor
- BioCity Biopharma
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of BC3195 in solid tumor, sponsored by BioCity Biopharma. Started Mar 2026; status: recruiting.
02
Drugs
BC3195
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07469774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469774.